ArticleJournal of advanced research2026
MeCP2 dysregulation inhibits mitophagy and impairs neural development in cortical organoids.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- MECP2 mutations disrupt pluripotent stem cell fate through remodeling of the three-dimensional genome.Cell death & disease · 2026Article
- Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The embedding of stress: mitophagy as a mechanism for the central nervous system (CNS) programming and lifelong disease vulnerability.Frontiers in cell and developmental biology · 2026Review
- MECP2 Duplication Uncouples Mitochondrial and Purine Metabolism During neuronal maturation.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMethylated CpG-binding protein 2 (MeCP2) plays a critical role in the normal development and function of the nervous system. Mutations in MeCP2 have been linked to neurodevelopmental disorders, potentially because of mitochondrial dysfunction and impaired mitophagy. However, the underlying mechanisms remain poorly understood. Investigating the role of MeCP2 in the regulation of mitophagy is essential for elucidating the pathogenesis of these disorders.
objectivesThe aim of the present study was to explore the molecular mechanisms by which MeCP2 regulates mitophagy and determine how its dysfunction contributes to neurodevelopmental abnormalities using cortical organoids (COs) derived from MeCP2 mutant induced pluripotent stem cells (iPSCs).
methodsCRISPR-Cas9 technology was used to generate MeCP2 mutant iPSCs, which were then differentiated into cortical organoids. Growth, proliferation, and differentiation of neural stem cells in these organoids were analysed. Single-cell RNA sequencing was performed to assess the changes in gene expression, focusing on mitophagy-related genes. MeCP2 occupancy at the BNIP3L transcription start site (TSS) was also examined.
resultsMeCP2 mutant COs exhibited growth inhibition, abnormal proliferation, and disrupted neural stem cell differentiation. Single-cell RNA sequencing revealed a significant downregulation of BNIP3L, a key mitophagy receptor. MeCP2 was found to occupy the BNIP3L TSS, leading to suppressed BNIP3L expression and impaired mitophagy in COs.
conclusionThe obtained findings demonstrate that MeCP2 regulates mitophagy by modulating BNIP3L expression, and its dysfunction leads to mitochondrial accumulation and neurodevelopmental abnormalities. The present study highlights the critical role of MeCP2 in maintaining mitochondrial homeostasis and provides insights into the molecular mechanisms underlying MeCP2-related neurodevelopmental disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.